Physician profile
Christine E Ryan
NPI 1770013542
$15,918.83
in general payments reported to CMS, 2019-2025
10 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $70.47 · 2024: $1,435 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,025.60 |
| Food and Beverage | $718.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,993.40 | 2025 | Columvi, Lunsumio |
| Beone Medicines USA, INC. | $4,804.10 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $3,768.00 | 2022-2025 | Calquence |
| Astrazeneca Uk Limited | $2,010.00 | 2025 | Calquence |
| Genmab U.S., INC. | $123.64 | 2024-2025 | Epkinly |
| Genentech, INC. | $91.97 | 2022 | |
| Janssen Scientific Affairs, LLC | $70.47 | 2023 | Imbruvica |
| Incyte Corporation | $42.25 | 2024-2025 | Jakafi, Niktimvo |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.